Marvel Biosciences Corp Stock Fundamentals
| MRVL Stock | 0.17 0.01 6.25% |
Marvel Biosciences Corp fundamentals help investors to digest information that contributes to Marvel Biosciences' financial success or failures. It also enables traders to predict the movement of Marvel Stock. The fundamental analysis module provides a way to measure Marvel Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marvel Biosciences stock.
EBIT is likely to climb to about (2.1 M) in 2024. Net Loss is likely to drop to about (2.4 M) in 2024. Marvel | Select Account or Indicator |
Marvel Biosciences Corp Company Return On Asset Analysis
Marvel Biosciences' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Marvel Biosciences Return On Asset | -1.54 |
Most of Marvel Biosciences' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marvel Biosciences Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Marvel Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Marvel Biosciences is extremely important. It helps to project a fair market value of Marvel Stock properly, considering its historical fundamentals such as Return On Asset. Since Marvel Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Marvel Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Marvel Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Marvel Net Tangible Assets
Net Tangible Assets |
|
Based on the latest financial disclosure, Marvel Biosciences Corp has a Return On Asset of -1.5364. This is 82.44% lower than that of the Biotechnology sector and 93.49% lower than that of the Health Care industry. The return on asset for all Canada stocks is notably higher than that of the company.
Marvel Biosciences Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Marvel Biosciences's current stock value. Our valuation model uses many indicators to compare Marvel Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Marvel Biosciences competition to find correlations between indicators driving Marvel Biosciences's intrinsic value. More Info.Marvel Biosciences Corp is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Marvel Biosciences' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Marvel Biosciences' earnings, one of the primary drivers of an investment's value.Marvel Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marvel Biosciences' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marvel Biosciences could also be used in its relative valuation, which is a method of valuing Marvel Biosciences by comparing valuation metrics of similar companies.Marvel Biosciences is currently under evaluation in return on asset category among its peers.
Marvel Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Marvel Biosciences from analyzing Marvel Biosciences' financial statements. These drivers represent accounts that assess Marvel Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Marvel Biosciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.9M | 4.2M | 2.8M | 3.2M | 2.9M | 2.3M | |
| Enterprise Value | 2.6M | 1.9M | 2.2M | 3.6M | 3.3M | 1.8M |
Marvel Fundamentals
| Return On Equity | -3.8 | ||||
| Return On Asset | -1.54 | ||||
| Current Valuation | 8.9 M | ||||
| Shares Outstanding | 44.79 M | ||||
| Shares Owned By Insiders | 26.66 % | ||||
| Number Of Shares Shorted | 267 | ||||
| Price To Book | 226.82 X | ||||
| EBITDA | (2.19 M) | ||||
| Net Income | (2.29 M) | ||||
| Total Debt | 2.39 M | ||||
| Book Value Per Share | (0.07) X | ||||
| Cash Flow From Operations | (1.33 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (0.06) X | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 7.61 M | ||||
| Total Asset | 672.39 K | ||||
| Retained Earnings | (9.05 M) | ||||
| Working Capital | (720.09 K) | ||||
| Net Asset | 672.39 K |
About Marvel Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marvel Biosciences Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marvel Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marvel Biosciences Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 1 M | 864.3 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Marvel Stock Analysis
When running Marvel Biosciences' price analysis, check to measure Marvel Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marvel Biosciences is operating at the current time. Most of Marvel Biosciences' value examination focuses on studying past and present price action to predict the probability of Marvel Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marvel Biosciences' price. Additionally, you may evaluate how the addition of Marvel Biosciences to your portfolios can decrease your overall portfolio volatility.